General Information of Drug (ID: DMSAD87)

Drug Name
N-(4-amino-6-butoxy-5-cyanopyridin-2-yl)acetamide Drug Info
Synonyms N-(4-amino-6-butoxy-5-cyanopyridin-2-yl)acetamide; CHEMBL378980; SCHEMBL1145050; BDBM15960; Aminopyridine-Based Inhibitor 19d
Indication
Disease Entry ICD 11 Status REF
Discovery agent N.A. Investigative [1]
Cross-matching ID
PubChem CID
11507052
TTD Drug ID
DMSAD87

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Investigative Drug(s)
Clinical Trial Drug(s)
Patented Agent(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
N-(4-amino-5-cyano-6-phenylpyridin-2-yl)acetamide DMUFVM6 Discovery agent N.A. Investigative [1]
AS-601245 DMQ95EB Discovery agent N.A. Investigative [2]
Aminopyridine deriv. 2 DM94KQP Discovery agent N.A. Investigative [1]
IN-1166 DMMS6D3 Discovery agent N.A. Investigative [3]
N-(4-amino-5-cyano-6-ethoxypyridin-2-yl)acetamide DMY1FMG Discovery agent N.A. Investigative [1]
JNK-IN-8 DMLWYJB Discovery agent N.A. Investigative [4]
AC1LG8KT DMFKV97 Discovery agent N.A. Investigative [5]
ISIS 18078 DMHZPJ0 Solid tumour/cancer 2A00-2F9Z Investigative [6]
⏷ Show the Full List of 8 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
NKP-1339 DM5AWK1 Solid tumour/cancer 2A00-2F9Z Phase 1 [7]
PMID25991433-Compound-A1 DM89LF0 N. A. N. A. Patented [8]
PMID25991433-Compound-F2 DM37VIQ N. A. N. A. Patented [8]
7-azaindole derivative 1 DMQL5B7 N. A. N. A. Patented [8]
7-azaindole derivative 5 DMV3H98 N. A. N. A. Patented [8]
PMID25991433-Compound-P6 DMNDVC9 N. A. N. A. Patented [8]
PMID25991433-Compound-J3 DM17P3F N. A. N. A. Patented [8]
PMID25991433-Compound-P1 DMD8AX6 N. A. N. A. Patented [8]
PMID25991433-Compound-O3 DMVOWS5 N. A. N. A. Patented [8]
PMID25991433-Compound-L1 DM2135Y N. A. N. A. Patented [8]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
JNK2 messenger RNA (JNK2 mRNA) TT3IVG2 MK09_HUMAN Inhibitor [1]
Stress-activated protein kinase JNK1 (JNK1) TT0K6EO MK08_HUMAN Inhibitor [1]

References

1 Aminopyridine-based c-Jun N-terminal kinase inhibitors with cellular activity and minimal cross-kinase activity. J Med Chem. 2006 Jun 15;49(12):3563-80.
2 The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297-315.
3 Synthesis and biological evaluation of 4(5)-(6-alkylpyridin-2-yl)imidazoles as transforming growth factor-beta type 1 receptor kinase inhibitors. J Med Chem. 2007 Jun 28;50(13):3143-7.
4 Discovery of potent and selective covalent inhibitors of JNK. Chem Biol. 2012 Jan 27;19(1):140-54.
5 N-(3-Cyano-4,5,6,7-tetrahydro-1-benzothien-2-yl)amides as potent, selective, inhibitors of JNK2 and JNK3. Bioorg Med Chem Lett. 2007 Mar 1;17(5):1296-301.
6 US patent application no. 7,425,545, Modulation of C-reactive protein expression.
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1496).
8 c-Jun N-terminal kinase inhibitors: a patent review (2010 - 2014).Expert Opin Ther Pat. 2015;25(8):849-72.